San Francisco, CANCT07339176Now EnrollingIRB Ready

Neoplasms, Solid Tumor Clinical Trial in San Francisco, CA

Access cutting-edge neoplasms, solid tumor treatment through this phase 1/2 clinical trial at a research site in San Francisco. Study-provided care at no cost to qualified participants.

Sponsored by Onchilles Pharma Inc

Quick Self-Assessment

See if you qualify for this San Francisco location

Preparing your pre-screening questions…

Expert Care in San Francisco

Access neoplasms, solid tumor specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related neoplasms, solid tumor treatment provided free

Apply for This San Francisco Location

Check if you qualify for this neoplasms, solid tumor clinical trial in San Francisco, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to San Francisco

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit San Francisco site if eligible
  4. 4Begin participation

About This Neoplasms, Solid Tumor Study in San Francisco

The goal of this clinical trial is to learn if N17350 works to treat advanced solid tumors in adults. It will also learn about the safety of N17350 and help determine the best dose to use in future studies. The main questions it aims to answer are: 1. Does N17350 cause tumors to shrink or stop growing in some participants with advanced solid tumors? 2. Are there any side effects for participants when taking N17350? 3. What is the safest dose of N17350 and the dose that should be used for further study? 4. Researchers will give N17350 directly into tumor lesions using a needle (intratumoral injection). This is an open-label study, meaning all participants will receive N17350 and there is no placebo. Participants will: 1. Receive injections of N17350 into tumor lesions every second week for 8 or 12 weeks 2. Visit the clinic regularly for checkups, blood tests, and monitoring for side effects 3. Have imaging scans (such as CT or MRI) to measure tumors and assess response 4. Provide blood samples and, when required, tumor samples to help researchers understand how N17350 affects the tumor and the immune system

Sponsor: Onchilles Pharma Inc

Who Can Participate

Inclusion Criteria

Age ≥18 years (or legal age of consent in the study jurisdiction).
Able to provide written informed consent and willing/able to comply with study procedures, visits, and follow-up.
Advanced solid tumor malignancy (excluding lymphoma and other hematologic malignancies), with disease that has progressed on, is intolerant of, or is ineligible for standard therapies known to provide clinical benefit, or for whom no standard therapy is available.
ECOG performance status 0-1.
Measurable disease per IT-RECIST (Parts A1/A2) and RECIST v1.1 (Part A3), as applicable.
At least one injectable tumor lesion, meeting superficial or visceral criteria and deemed safe/accessible for injection:
Superficial lesions: ≥10 mm in longest diameter (or multiple lesions each ≥5 mm with aggregate longest diameter ≥10 mm), and ≤80 mm, accessible for direct injection (± ultrasound guidance).
Visceral lesions: ≥10 mm and ≤50 mm in longest diameter, accessible for direct injection.
Injected lesions must not involve/encase major blood vessels or otherwise pose an unacceptable bleeding/vascular risk, per investigator assessment and imaging review (as applicable).
Expansion (Part A3): at least 1 measurable lesion and at least 1 additional injectable lesion suitable for injection.
Adequate recovery from prior therapy: toxicities from prior anticancer treatment resolved to Grade ≤1 or baseline (except alopecia, controlled endocrine toxicities, or other stable toxicities as allowed per protocol/sponsor).
Adequate organ function, including hepatic, renal, and coagulation parameters per protocol-defined thresholds.
Adequate bone marrow function without transfusion support within 7 days prior to enrollment, per protocol-defined thresholds.
Tumor tissue requirements: willingness to provide a pre-treatment tumor biopsy and on-study post-treatment biopsy, if an accessible lesion is available and safe for biopsy, and biopsy does not interfere with injection/response assessment; and/or availability of archival tumor tissue (obtained within 2 years prior to treatment), per protocol.
Contraception requirements: participants of reproductive potential agree to use effective contraception and avoid pregnancy/fathering children from screening through 30 days after last dose; women of childbearing potential must have a negative pregnancy test within 14 days prior to first dose, per protocol.

Exclusion Criteria

Serious psychiatric, medical, or other condition that would interfere with study participation or protocol procedures, in the investigator's judgment.
History of solid organ transplant.
Alpha-1 antitrypsin deficiency.
Hereditary or acquired bleeding disorder/coagulation factor deficiency.
Active autoimmune disease requiring systemic treatment within the past 6 months, except clinically stable autoimmune conditions in remission not requiring systemic therapy (per protocol).
Baseline QTcF \>480 ms.
Pregnant or breastfeeding.
Prior severe immune-mediated adverse event (imAE) from immunotherapy: ≥Grade 3 imAE within the past 16 weeks, any Grade 4 life-threatening imAE, or any neurologic/ocular AE of any grade (except controlled endocrine AEs on stable replacement therapy per protocol).
Another active malignancy (current or within the past 2 years) other than the disease under study, except specified low-risk cancers treated with curative intent or under active surveillance (per protocol).
Recent anticancer therapy: receipt of systemic anticancer therapy (including investigational agents) within 2 weeks prior to first dose (or 4 weeks for monoclonal antibodies/ADCs/other long half-life biologics), or within 5 half-lives, whichever is shorter.
Recent radiotherapy within 2 weeks prior to first dose.
Unresolved toxicity from prior anticancer therapy to \>Grade 1 or not at baseline (except Grade ≤2 neuropathy and other allowed exceptions per protocol).
Uncontrolled or unstable brain metastases (eligible only if neurologically stable for ≥4 weeks, and off steroids or on stable/decreasing steroids ≤10 mg/day prednisone equivalent; carcinomatous meningitis excluded).
Active infection requiring systemic antibacterial, antifungal, or antiviral therapy within 14 days prior to first dose.
Chronic viral infections not meeting protocol criteria:
HBV with detectable DNA unless on appropriate antiviral therapy
Active HCV with detectable HCV RNA (treated HCV permitted if RNA undetectable)
HIV infection with CD4+ count \<300/μL, detectable viral load, or HIV-related illness within 6 months
Use of systemic anticoagulants (e.g., warfarin, LMWH, DOACs) within 14 days prior to first dose.
Chronic systemic corticosteroids \>10 mg/day prednisone equivalent, or systemic immunosuppressive/anti-inflammatory medications within 4 weeks prior to first dose, except permitted topical/inhaled/local formulations or short courses for premedication per protocol.
Known allergy/hypersensitivity to N17350 or any excipients.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in San Francisco?

Yes, this clinical trial (NCT07339176) has an active research site in San Francisco, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Neoplasms, Solid Tumor Treatment Options in San Francisco, CA

If you're searching for neoplasms, solid tumor treatment options in San Francisco, CA, this clinical trial (NCT07339176) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our San Francisco research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced neoplasms, solid tumor specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all neoplasms, solid tumor clinical trials near you to find additional studies recruiting in your area.

More Advanced Solid Tumors Trials in San Francisco, CA

See all advanced solid tumors clinical trials recruiting in San Francisco — not just this study.

Browse Advanced Solid Tumors Trials in San Francisco →

Browse More Trials by Condition

Advanced Solid Tumors TrialsMultiple Sclerosis TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in San Francisco?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · San Francisco, CA